Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (21)

2022

  1. Alkylating Agent-Induced Toxicity and Melatonin-Based Therapies

    Frontiers in Pharmacology, Vol. 13

  2. Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?

    Cellular and Molecular Neurobiology, Vol. 42, Núm. 3, pp. 489-500

  3. Editorial: Therapeutic Advances in Melatonin Research

    Frontiers in Pharmacology

2021

  1. In Silico Prediction of the Toxic Potential of Neuroprotective Bifunctional Molecules Based on Chiral N-Propargyl-1,2-amino Alcohol Derivatives

    Chemical Research in Toxicology, Vol. 34, Núm. 5, pp. 1245-1249

  2. The coronavirus disease 2019 (Covid-19): Key emphasis on melatonin safety and therapeutic efficacy

    Antioxidants, Vol. 10, Núm. 7

2020

  1. Cerebral ischemia and traumatic brain injury: Protection by melatonin

    Melatonin: Production, Functions and Benefits (Nova Science Publishers, Inc.), pp. 231-255

  2. Detection of neurological and ophthalmological pathologies with optical coherence tomography using retinal thickness measurements: A bibliometric study

    Applied Sciences (Switzerland), Vol. 10, Núm. 16

  3. In Vitro and in Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases

    ACS Chemical Neuroscience, Vol. 11, Núm. 22, pp. 3793-3801

  4. Melatonin reduces NLRP3 inflammasome activation by increasing α7 nAChR-mediated autophagic flux

    Antioxidants, Vol. 9, Núm. 12, pp. 1-18

  5. Melatonin's efficacy in stroke patients; a matter of dose? A systematic review

    Toxicology and Applied Pharmacology, Vol. 392

  6. Scientific production on melatonin from a bibliometric perspective

    Melatonin: Production, Functions and Benefits (Nova Science Publishers, Inc.), pp. 1-17

  7. Understanding the oncostatic actions displayed by melatonin in colorectal cancer therapy

    Future Medicinal Chemistry, Vol. 12, Núm. 13, pp. 1201-1204

2019

  1. Potential of melatonin as adjuvant therapy of oral cancer in the era of epigenomics

    Cancers, Vol. 11, Núm. 11

2018

  1. A history of the pharmacological treatment of bipolar disorder

    International Journal of Molecular Sciences, Vol. 19, Núm. 7

  2. In silico assessment of the metabolism and its safety significance of multitarget propargylamine ASS234

    CNS Neuroscience and Therapeutics

  3. Melatonin: A hypothesis for Kawasaki disease treatment

    Medical Hypotheses, Vol. 119, pp. 6-10

  4. Modulation of Heat Shock Response Proteins by ASS234, Targeted for Neurodegenerative Diseases Therapy

    Chemical Research in Toxicology, Vol. 31, Núm. 9, pp. 839-842

  5. Neuroinflammation Signaling Modulated by ASS234, a Multitarget Small Molecule for Alzheimer's Disease Therapy

    ACS Chemical Neuroscience, Vol. 9, Núm. 12, pp. 2880-2885

2017

  1. 5-Methyl-: N -(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5 H -indolo[2,3- b] quinolin-11-amine: A highly potent human cholinesterase inhibitor

    MedChemComm, Vol. 8, Núm. 6, pp. 1307-1317

  2. Corrigendum: Melatonin and nitrones as potential therapeutic agents for stroke [Front. Aging Neurosci., 8 (2016) (281)] DOI:10.3389/fnagi.2016.00281

    Frontiers in Aging Neuroscience